Kazim A. Sheikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazim A. Sheikh has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Gang Zhang
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4 shared publicationsJohn W. Griffin
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
4 shared publications- Ronald L. Schnaar
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine
3 shared publications C. Y. Li
2 shared publicationsJ. W. Griffin
2 shared publications- Jiangyang Zhang
Department of Radiology, New York University School of Medicine, New York, NY, USA
2 shared publications
Latest Publications
- 1 August 2008
- Published by Elsevier in Experimental Neurology
- Vol. 212 (2) , 448-457
Magnetic resonance imaging of mouse skeletal muscle to measure denervation atrophy
- 1 August 2008
- Published by Elsevier in Experimental Neurology
- Vol. 212 (2) , 448-457
Magnetic resonance imaging of mouse skeletal muscle to measure denervation atrophy
- 1 October 2007
- Published by Elsevier in Neurobiology of Disease
- Vol. 28 (1) , 113-121
Anti-ganglioside antibodies alter presynaptic release and calcium influx
- 1 October 2007
- Published by Elsevier in Neurobiology of Disease
- Vol. 28 (1) , 113-121
Anti-ganglioside antibodies alter presynaptic release and calcium influx
- Open Access
- 3 January 2007
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 27 (1) , 27-34
Passive Immunization with Anti-Ganglioside Antibodies Directly Inhibits Axon Regeneration in an Animal Model
Recent studies have proposed that neurite outgrowth is influenced by specific nerve cell surface gangliosides, which are sialic acid-containing glycosphingolipids highly enriched in the mammalian nervous system. For example, the endogenous lectin, myelin-associated glycoprotein (MAG), is reported to bind to axonal gangliosides (GD1a and GT1b) to inhibit neurite outgrowth. Clustering of gangliosides in the absence of inhibitors such as MAG is also shown to inhibit neurite outgrowth in culture. In some human autoimmune PNS and CNS disorders, autoantibodies against GD1a or other gangliosides are implicated in pathophysiology. Because of neurobiological and clinical relevance, we asked whether anti-GD1a antibodies inhibit regeneration of injured axonsin vivo. Passive transfer of anti-GD1a antibody severely inhibited axon regeneration after PNS injury in mice. In mutant mice with altered ganglioside or complement expression, inhibition by antibodies was mediated directly through GD1a and was independent of complement-induced cytolytic injury. The impaired regenerative responses and ultrastructure of injured peripheral axons mimicked the abortive regeneration typically seen after CNS injury. These data demonstrate that inhibition of axon regeneration is induced directly by engaging cell surface gangliosidesin vivoand imply that circulating autoimmune antibodies can inhibit axon regeneration through neuronal gangliosides independent of endogenous regeneration inhibitors such as MAG.
- 3 January 2007
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 27 (1) , 27-34
Open AccessPassive Immunization with Anti-Ganglioside Antibodies Directly Inhibits Axon Regeneration in an Animal Model
Recent studies have proposed that neurite outgrowth is influenced by specific nerve cell surface gangliosides, which are sialic acid-containing glycosphingolipids highly enriched in the mammalian nervous system. For example, the endogenous lectin, myelin-associated glycoprotein (MAG), is reported to bind to axonal gangliosides (GD1a and GT1b) to inhibit neurite outgrowth. Clustering of gangliosides in the absence of inhibitors such as MAG is also shown to inhibit neurite outgrowth in culture. In some human autoimmune PNS and CNS disorders, autoantibodies against GD1a or other gangliosides are implicated in pathophysiology. Because of neurobiological and clinical relevance, we asked whether anti-GD1a antibodies inhibit regeneration of injured axonsin vivo. Passive transfer of anti-GD1a antibody severely inhibited axon regeneration after PNS injury in mice. In mutant mice with altered ganglioside or complement expression, inhibition by antibodies was mediated directly through GD1a and was independent of complement-induced cytolytic injury. The impaired regenerative responses and ultrastructure of injured peripheral axons mimicked the abortive regeneration typically seen after CNS injury. These data demonstrate that inhibition of axon regeneration is induced directly by engaging cell surface gangliosidesin vivoand imply that circulating autoimmune antibodies can inhibit axon regeneration through neuronal gangliosides independent of endogenous regeneration inhibitors such as MAG.
- 25 April 2005
- Published by Wiley in Annals of Neurology
- Vol. 57 (5) , 768-772
Overlap of pathology in paralytic rabies and axonal Guillain–Barré syndrome
We describe clinical and pathological features of a case of paralytic rabies with acute axonal neuropathy that closely resembled axonal Guillain–Barré syndrome. This case emphasizes that there is overlap of both clinical and pathological features in paralytic rabies and axonal Guillain–Barré syndrome. These findings raise the possibility that infectious and autoimmune etiologies can lead to similar morphological changes in the nerves. Ann Neurol 2005;57:768–772
- 25 April 2005
- Published by Wiley in Annals of Neurology
- Vol. 57 (5) , 768-772
Overlap of pathology in paralytic rabies and axonal Guillain–Barré syndrome
We describe clinical and pathological features of a case of paralytic rabies with acute axonal neuropathy that closely resembled axonal Guillain–Barré syndrome. This case emphasizes that there is overlap of both clinical and pathological features in paralytic rabies and axonal Guillain–Barré syndrome. These findings raise the possibility that infectious and autoimmune etiologies can lead to similar morphological changes in the nerves. Ann Neurol 2005;57:768–772
- 19 July 2004
- Published by Wiley in Annals of Neurology
- Vol. 56 (2) , 228-239
An anti‐ganglioside antibody‐secreting hybridoma induces neuropathy in mice
Immune responses against gangliosides are strongly implicated in the pathogenesis of some variants of Guillain–Barré syndrome (GBS). For example, IgG antibodies against GM1, GD1a, and related gangliosides are frequently present in patients with post‐Campylobacter acute motor axonal neuropathy (AMAN) variant of GBS, and immunization of rabbits with GM1 has produced a model of AMAN. However, the role of anti‐ganglioside antibodies in GBS continues to be debated because of lack of a passive transfer model. We recently have raised several monoclonal IgG anti‐ganglioside antibodies. We passively transfer these antibodies by intraperitoneal hybridoma implantation and by systemic administration of purified anti‐ganglioside antibodies in mice. Approximately half the animals implanted with an intraperitoneal clone of anti‐ganglioside antibody‐secreting hybridoma developed a patchy, predominantly axonal neuropathy affecting a small proportion of nerve fibers. In contrast to hybridoma implantation, passive transfer with systemically administered anti‐ganglioside antibodies did not cause nerve fiber degeneration despite high titre circulating antibodies. Blood–nerve barrier studies indicate that animals implanted with hybridoma had leaky blood–nerve barrier compared to mice that received systemically administered anti‐ganglioside antibodies. Our findings suggest that in addition to circulating antibodies, factors such as antibody accessibility and nerve fiber resistance to antibody‐mediated injury play a role in the development of neuropathy. Ann Neurol 2004;56:228–239
- 19 July 2004
- Published by Wiley in Annals of Neurology
- Vol. 56 (2) , 228-239
An anti‐ganglioside antibody‐secreting hybridoma induces neuropathy in mice
Immune responses against gangliosides are strongly implicated in the pathogenesis of some variants of Guillain–Barré syndrome (GBS). For example, IgG antibodies against GM1, GD1a, and related gangliosides are frequently present in patients with post‐Campylobacter acute motor axonal neuropathy (AMAN) variant of GBS, and immunization of rabbits with GM1 has produced a model of AMAN. However, the role of anti‐ganglioside antibodies in GBS continues to be debated because of lack of a passive transfer model. We recently have raised several monoclonal IgG anti‐ganglioside antibodies. We passively transfer these antibodies by intraperitoneal hybridoma implantation and by systemic administration of purified anti‐ganglioside antibodies in mice. Approximately half the animals implanted with an intraperitoneal clone of anti‐ganglioside antibody‐secreting hybridoma developed a patchy, predominantly axonal neuropathy affecting a small proportion of nerve fibers. In contrast to hybridoma implantation, passive transfer with systemically administered anti‐ganglioside antibodies did not cause nerve fiber degeneration despite high titre circulating antibodies. Blood–nerve barrier studies indicate that animals implanted with hybridoma had leaky blood–nerve barrier compared to mice that received systemically administered anti‐ganglioside antibodies. Our findings suggest that in addition to circulating antibodies, factors such as antibody accessibility and nerve fiber resistance to antibody‐mediated injury play a role in the development of neuropathy. Ann Neurol 2004;56:228–239
- Open Access
- 26 February 2004
- Published by Oxford University Press (OUP) in Brain
- Vol. 127 (5) , 1085-1100
Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies
Antibodies against GD1a, GM1 and related gangliosides are frequently present in patients with the motor variant of Guillain–Barré syndrome (GBS), and their pathological role in this variant of GBS is now widely accepted. However, two basic issues related to anti‐ganglioside antibody‐mediated neural injury are not completely resolved: (i) some anti‐ganglioside antibodies can cross‐react with glycoproteins and therefore the nature of antigens targeted by these antibodies is not well established; and (ii) although pathological studies suggest that complement activation occurs in GBS, experimental data for the role of complement remain inconclusive. To address these issues, we developed and characterized a simple anti‐ganglioside antibody‐mediated cytotoxicity assay. Our results demonstrate first, that both GBS sera containing anti‐ganglioside antibodies and monoclonal anti‐ganglioside antibodies cause neuronal cell lysis by targeting specific cell surface gangliosides, and secondly, that this cell lysis is complement dependent. In this assay, the GD1a cell membrane pool appears to be more susceptible to anti‐ganglioside antibody‐mediated injury than the GM1 pool. Further, human intravenous immunoglobulin (IVIg), now a standard treatment for GBS, significantly decreased cytotoxicity in this assay. Our data indicate that the mechanisms of IVIg‐mediated protection in this assay include anti‐idiotypic antibodies and downregulation of complement activation. This simple cytotoxicity assay can potentially be used for screening of (i) pathogenic anti‐ganglioside antibodies in patients with immune‐mediated neuropathies; and (ii) new/experimental therapies to prevent anti‐ganglioside antibody‐mediated neural injury.
- 26 February 2004
- Published by Oxford University Press (OUP) in Brain
- Vol. 127 (5) , 1085-1100
Open AccessAnti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies
Antibodies against GD1a, GM1 and related gangliosides are frequently present in patients with the motor variant of Guillain–Barré syndrome (GBS), and their pathological role in this variant of GBS is now widely accepted. However, two basic issues related to anti‐ganglioside antibody‐mediated neural injury are not completely resolved: (i) some anti‐ganglioside antibodies can cross‐react with glycoproteins and therefore the nature of antigens targeted by these antibodies is not well established; and (ii) although pathological studies suggest that complement activation occurs in GBS, experimental data for the role of complement remain inconclusive. To address these issues, we developed and characterized a simple anti‐ganglioside antibody‐mediated cytotoxicity assay. Our results demonstrate first, that both GBS sera containing anti‐ganglioside antibodies and monoclonal anti‐ganglioside antibodies cause neuronal cell lysis by targeting specific cell surface gangliosides, and secondly, that this cell lysis is complement dependent. In this assay, the GD1a cell membrane pool appears to be more susceptible to anti‐ganglioside antibody‐mediated injury than the GM1 pool. Further, human intravenous immunoglobulin (IVIg), now a standard treatment for GBS, significantly decreased cytotoxicity in this assay. Our data indicate that the mechanisms of IVIg‐mediated protection in this assay include anti‐idiotypic antibodies and downregulation of complement activation. This simple cytotoxicity assay can potentially be used for screening of (i) pathogenic anti‐ganglioside antibodies in patients with immune‐mediated neuropathies; and (ii) new/experimental therapies to prevent anti‐ganglioside antibody‐mediated neural injury.
- Open Access
- 1 November 2002
- Published by Oxford University Press (OUP) in Brain
- Vol. 125 (11) , 2491-2506
Localization of major gangliosides in the PNS: implications for immune neuropathies
Antibodies targeting major gangliosides that are broadly distributed in the nervous system are sometimes associated with clinical symptoms that imply selective nerve damage. For example, anti‐GD1a antibodies are associated with acute motor axonal neuropathy (AMAN), a form of Guillain–Barré syndrome that selectively affects motor nerves, despite reports that GD1a is present in human axons and myelin and is not expressed differentially in motor versus sensory roots. We used a series of high‐affinity monoclonal antibodies (mAbs) against the major nervous system gangliosides GM1, GD1a, GD1b and GT1b to test whether any of them bind motor or sensory fibres differentially in rodent and human peripheral nerves. The following observations were made. (i) Some of the anti‐GD1a antibodies preferentially stained motor fibres, supporting the association of human anti‐GD1a antibodies with predominant motor neuropathies such as AMAN. (ii) A GD1b antibody preferentially stained the large dorsal root ganglion (DRG) neurones, in keeping with the proposed role of human anti‐GD1b antibodies in sensory ataxic neuropathies. (iii) Two mAbs with broad structural cross‐reactivity bound to both gangliosides and peripheral nerve proteins. (iv) Myelin was poorly stained; all clones stained axons nearly exclusively. Our findings suggest that anti‐ganglioside antibody fine specificity as well as differences in ganglioside accessibility in axons and myelin influence the selectivity of injury to different fibre systems and cell types in human autoimmune neuropathies.
- 1 November 2002
- Published by Oxford University Press (OUP) in Brain
- Vol. 125 (11) , 2491-2506
Open AccessLocalization of major gangliosides in the PNS: implications for immune neuropathies
Antibodies targeting major gangliosides that are broadly distributed in the nervous system are sometimes associated with clinical symptoms that imply selective nerve damage. For example, anti‐GD1a antibodies are associated with acute motor axonal neuropathy (AMAN), a form of Guillain–Barré syndrome that selectively affects motor nerves, despite reports that GD1a is present in human axons and myelin and is not expressed differentially in motor versus sensory roots. We used a series of high‐affinity monoclonal antibodies (mAbs) against the major nervous system gangliosides GM1, GD1a, GD1b and GT1b to test whether any of them bind motor or sensory fibres differentially in rodent and human peripheral nerves. The following observations were made. (i) Some of the anti‐GD1a antibodies preferentially stained motor fibres, supporting the association of human anti‐GD1a antibodies with predominant motor neuropathies such as AMAN. (ii) A GD1b antibody preferentially stained the large dorsal root ganglion (DRG) neurones, in keeping with the proposed role of human anti‐GD1b antibodies in sensory ataxic neuropathies. (iii) Two mAbs with broad structural cross‐reactivity bound to both gangliosides and peripheral nerve proteins. (iv) Myelin was poorly stained; all clones stained axons nearly exclusively. Our findings suggest that anti‐ganglioside antibody fine specificity as well as differences in ganglioside accessibility in axons and myelin influence the selectivity of injury to different fibre systems and cell types in human autoimmune neuropathies.
- Open Access
- 1 April 2002
- Published by Oxford University Press (OUP) in Brain
- Vol. 125 (4) , 904-911
Anti‐myelin‐associated glycoprotein antibodies alter neurofilament spacing
Axon calibre is crucial to efficient impulse transmission in the peripheral nervous system. Neurofilament numbers determine gross axonal diameter, but intra‐axonal distribution depends on the phosphorylation status of neurofilament sidearms. Myelin‐associated glycoprotein (MAG) has been implicated in the signalling cascade controlling neurofilament phosphorylation and hence in the control of axon calibre. In an electron microscopic morphometric study we measured nearest neighbour neurofilament distances (NNND) in the axons of sural nerves from patients with anti‐MAG paraproteinaemic neuropathies and compared these with normal human sural nerves and those from patients with Guillain–Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Axon calibre was similar in all groups. In normal human sural nerves, axonal NNND was correlated with axonal diameter (r = 0.56). In diseased axons this correlation did not exist. The NNND was significantly reduced in demyelinated axons (30.5 2.2 nm) and those with widely spaced myelin (28.9 1.3 nm) from patients with anti‐MAG antibodies compared with normal axons from normal patients (39.8 3.2 nm) or those with demyelinating neuropathy (35.8 4.6 nm). This reinforces the hypothesis that MAG is involved in the control of neurofilament spacing through sidearm phosphorylation and demonstrates a MAG‐mediated pathogenic effect of the anti‐MAG antibody in peripheral nerves.
- 1 April 2002
- Published by Oxford University Press (OUP) in Brain
- Vol. 125 (4) , 904-911
Open AccessAnti‐myelin‐associated glycoprotein antibodies alter neurofilament spacing
Axon calibre is crucial to efficient impulse transmission in the peripheral nervous system. Neurofilament numbers determine gross axonal diameter, but intra‐axonal distribution depends on the phosphorylation status of neurofilament sidearms. Myelin‐associated glycoprotein (MAG) has been implicated in the signalling cascade controlling neurofilament phosphorylation and hence in the control of axon calibre. In an electron microscopic morphometric study we measured nearest neighbour neurofilament distances (NNND) in the axons of sural nerves from patients with anti‐MAG paraproteinaemic neuropathies and compared these with normal human sural nerves and those from patients with Guillain–Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Axon calibre was similar in all groups. In normal human sural nerves, axonal NNND was correlated with axonal diameter (r = 0.56). In diseased axons this correlation did not exist. The NNND was significantly reduced in demyelinated axons (30.5 2.2 nm) and those with widely spaced myelin (28.9 1.3 nm) from patients with anti‐MAG antibodies compared with normal axons from normal patients (39.8 3.2 nm) or those with demyelinating neuropathy (35.8 4.6 nm). This reinforces the hypothesis that MAG is involved in the control of neurofilament spacing through sidearm phosphorylation and demonstrates a MAG‐mediated pathogenic effect of the anti‐MAG antibody in peripheral nerves.